Furamist AZ is the latest and the most advanced combination nasal spray for treating allergic rhinitis containing Fluticasone Furoate (27.5mcg) and Reformulated Azelastine hydrochloride (140mcg).
Optimal treatment of patients with allergic rhinitis can be achieved only by managing both the early phase reaction (EPR) and late phase reaction (LPR). An H 1 receptor antagonist most effectively manages the symptoms observed in the EPR where as the effects of the LPR are best managed with corticosteroids.
Fluticasone Furoate is a novel glucocorticoid with high systemic clearance, high receptor affinity and low oral bioavailability. It is effective in controlling the nasal as well as ocular symptoms of allergic rhinitis.
Reformulated azelastine with a sorbitol based vehicle and sucralose as a taste masking agent was developed to reduce the bitter taste of the original azelastine hydrochloride.
Clinical studies conducted for safety, tolerability and pharmacokinetic parameters of reformulated azelastine was similar to original azelastine. Antihistamines relieve pruritus, sneezing rhinorrhoea and ocular symptoms but do not control nasal stuffiness. Intranasal corticosteroids can attenuate all nasal symptoms, but are most effective against rhinorrhoea and stuffiness. Thus the treatment that combines an antihistamine and a corticosteroid nasal spray may maximize clinical efficacy.
Therefore the ideal pharmacological therapy for allergic rhinitis would be a drug that possessed not only H 1 receptor antagonist activity but also anti-inflammatory activity. The recommended dosage of Furamist-AZ for adults and children 5 years and older is 1 spray/nostril twice daily.